# Fortunato Ciardiello

## List of Publications by Citations



| | | | |
|---|---|---|---|
| 360 papers | 24,391 citations | 71 h-index | 148 g-index |
| 375 ext. papers | 27,768 ext. citations | 6.9 avg, IF | 6.73 L-index |

| # | Paper | IF | Citations |
|---|---|---|---|
| 360 | Epidermal growth factor-related peptides and their receptors in human malignancies. *Critical Reviews in Oncology/Hematology*, **1995**, 19, 183-232 | 7 | 2150 |
| 359 | Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis. *Lancet Oncology, The*, **2010**, 11, 753-62 | 21.7 | 1653 |
| 358 | EGFR antagonists in cancer treatment. *New England Journal of Medicine*, **2008**, 358, 1160-74 | 59.2 | 1570 |
| 357 | Cetuximab plus irinotecan, fluorouracil, and leucovorin as first-line treatment for metastatic colorectal cancer: updated analysis of overall survival according to tumor KRAS and BRAF mutation status. *Journal of Clinical Oncology*, **2011**, 29, 2011-9 | 2.2 | 1463 |
| 356 | Chronic inflammation and oxidative stress in human carcinogenesis. *International Journal of Cancer*, **2007**, 121, 2381-6 | 7.5 | 661 |
| 355 | Dual-targeted therapy with trastuzumab and lapatinib in treatment-refractory, KRAS codon 12/13 wild-type, HER2-positive metastatic colorectal cancer (HERACLES): a proof-of-concept, multicentre, open-label, phase 2 trial. *Lancet Oncology, The*, **2016**, 17, 738-746 | 21.7 | 533 |
| 354 | Fluorouracil, leucovorin, and irinotecan plus cetuximab treatment and RAS mutations in colorectal cancer. *Journal of Clinical Oncology*, **2015**, 33, 692-700 | 2.2 | 515 |
| 353 | Encorafenib, Binimetinib, and Cetuximab in V600E-Mutated Colorectal Cancer. *New England Journal of Medicine*, **2019**, 381, 1632-1643 | 59.2 | 481 |
| 352 | KRAS, BRAF, PIK3CA, and PTEN mutations: implications for targeted therapies in metastatic colorectal cancer. *Lancet Oncology, The*, **2011**, 12, 594-603 | 21.7 | 453 |
| 351 | Addition of cetuximab to chemotherapy as first-line treatment for KRAS wild-type metastatic colorectal cancer: pooled analysis of the CRYSTAL and OPUS randomised clinical trials. *European Journal of Cancer*, **2012**, 48, 1466-75 | 7.5 | 432 |
| 350 | ZD6474, an orally available inhibitor of KDR tyrosine kinase activity, efficiently blocks oncogenic RET kinases. *Cancer Research*, **2002**, 62, 7284-90 | 10.1 | 425 |
| 349 | Prognostic and Predictive Relevance of Primary Tumor Location in Patients With RAS Wild-Type Metastatic Colorectal Cancer: Retrospective Analyses of the CRYSTAL and FIRE-3 Trials. *JAMA Oncology*, **2017**, 3, 194-201 | 13.4 | 409 |
| 348 | Treatment of gastric cancer. *World Journal of Gastroenterology*, **2014**, 20, 1635-49 | 5.6 | 394 |
| 347 | Implications for KRAS status and EGFR-targeted therapies in metastatic CRC. *Nature Reviews Clinical Oncology*, **2009**, 6, 519-27 | 19.4 | 341 |
| 346 | Antitumor activity of ZD6474, a vascular endothelial growth factor receptor tyrosine kinase inhibitor, in human cancer cells with acquired resistance to antiepidermal growth factor receptor therapy. *Clinical Cancer Research*, **2004**, 10, 784-93 | 12.9 | 309 |
| 345 | Phase II trial of cetuximab in combination with fluorouracil, leucovorin, and oxaliplatin in the first-line treatment of metastatic colorectal cancer. *Journal of Clinical Oncology*, **2007**, 25, 5225-32 | 2.2 | 273 |
| 344 | A meta-analysis on the interaction between HER-2 expression and response to endocrine treatment in advanced breast cancer. *Clinical Cancer Research*, **2005**, 11, 4741-8 | 12.9 | 271 |

| | | | |
|---|---|---|---|
| 343 | Symptomatic toxicities experienced during anticancer treatment: agreement between patient and physician reporting in three randomized trials. *Journal of Clinical Oncology*, **2015**, 33, 910-5 | 2.2 | 262 |
| 342 | Mechanisms of resistance to EGFR-targeted drugs: lung cancer. *ESMO Open*, **2016**, 1, e000060 | 6 | 229 |
| 341 | Antitumor effects of ZD6474, a small molecule vascular endothelial growth factor receptor tyrosine kinase inhibitor, with additional activity against epidermal growth factor receptor tyrosine kinase. *Clinical Cancer Research*, **2003**, 9, 1546-56 | 12.9 | 229 |
| 340 | Implication of the insulin-like growth factor-IR pathway in the resistance of non-small cell lung cancer cells to treatment with gefitinib. *Clinical Cancer Research*, **2007**, 13, 2795-803 | 12.9 | 222 |
| 339 | Atezolizumab with or without cobimetinib versus regorafenib in previously treated metastatic colorectal cancer (IMblaze370): a multicentre, open-label, phase 3, randomised, controlled trial. *Lancet Oncology, The*, **2019**, 20, 849-861 | 21.7 | 201 |
| 338 | Prospective study of gefitinib in epidermal growth factor receptor fluorescence in situ hybridization-positive/phospho-Akt-positive or never smoker patients with advanced non-small-cell lung cancer: the ONCOBELL trial. *Journal of Clinical Oncology*, **2007**, 25, 2248-55 | 2.2 | 198 |
| 337 | First-line erlotinib followed by second-line cisplatin-gemcitabine chemotherapy in advanced non-small-cell lung cancer: the TORCH randomized trial. *Journal of Clinical Oncology*, **2012**, 30, 3002-11 | 2.2 | 193 |
| 336 | The effects of cetuximab alone and in combination with radiation and/or chemotherapy in lung cancer. *Clinical Cancer Research*, **2005**, 11, 795-805 | 12.9 | 165 |
| 335 | Enhancement of antitumor activity of ionizing radiation by combined treatment with the selective epidermal growth factor receptor-tyrosine kinase inhibitor ZD1839 (Iressa). *Clinical Cancer Research* , **2002**, 8, 3250-8 | 12.9 | 164 |
| 334 | Assessment of a HER2 scoring system for colorectal cancer: results from a validation study. *Modern Pathology*, **2015**, 28, 1481-91 | 9.8 | 144 |
| 333 | Pulmonary Large-Cell Neuroendocrine Carcinoma: From Epidemiology to Therapy. *Journal of Thoracic Oncology*, **2015**, 10, 1133-41 | 8.9 | 133 |
| 332 | Immunotherapy of colorectal cancer: Challenges for therapeutic efficacy. *Cancer Treatment Reviews* , **2019**, 76, 22-32 | 14.4 | 131 |
| 331 | Transformation of an established mouse mammary epithelial cell line following transfection with a human transforming growth factor alpha cDNA. *Molecular Carcinogenesis*, **1989**, 2, 1-11 | 5 | 129 |
| 330 | Predictive value of epidermal growth factor receptor expression for first-line chemotherapy plus cetuximab in patients with head and neck and colorectal cancer: analysis of data from the EXTREME and CRYSTAL studies. *European Journal of Cancer*, **2013**, 49, 1161-8 | 7.5 | 128 |
| 329 | Vascular endothelial growth factor receptor-1 contributes to resistance to anti-epidermal growth factor receptor drugs in human cancer cells. *Clinical Cancer Research*, **2008**, 14, 5069-80 | 12.9 | 127 |
| 328 | ALK inhibitors in the treatment of advanced NSCLC. *Cancer Treatment Reviews*, **2014**, 40, 300-6 | 14.4 | 125 |
| 327 | Upregulated stromal EGFR and vascular remodeling in mouse xenograft models of angiogenesis inhibitor-resistant human lung adenocarcinoma. *Journal of Clinical Investigation*, **2011**, 121, 1313-28 | 15.9 | 124 |
| 326 | Epidermal growth factor receptor tyrosine kinase inhibitors as anticancer agents. *Drugs*, **2000**, 60 Suppl 1, 25-32; discussion 41-2 | 12.1 | 124 |

| | | | |
|---|---|---|---|
| 325 | Key cancer cell signal transduction pathways as therapeutic targets. *European Journal of Cancer*, **2006**, 42, 290-4 | 7.5 | 118 |
| 324 | Binimetinib, Encorafenib, and Cetuximab Triplet Therapy for Patients With V600E-Mutant Metastatic Colorectal Cancer: Safety Lead-In Results From the Phase III BEACON Colorectal Cancer Study. *Journal of Clinical Oncology*, **2019**, 37, 1460-1469 | 2.2 | 114 |
| 323 | Increased TGF-as a mechanism of acquired resistance to the anti-EGFR inhibitor cetuximab through EGFR-MET interaction and activation of MET signaling in colon cancer cells. *Clinical Cancer Research*, **2013**, 19, 6751-65 | 12.9 | 111 |
| 322 | PARP inhibitors in ovarian cancer. *Cancer Treatment Reviews*, **2019**, 73, 1-9 | 14.4 | 110 |
| 321 | Pharmacogenomic and pharmacoproteomic studies of cetuximab in metastatic colorectal cancer: biomarker analysis of a phase I dose-escalation study. *Journal of Clinical Oncology*, **2010**, 28, 1181-9 | 2.2 | 99 |
| 320 | Intrapatient cetuximab dose escalation in metastatic colorectal cancer according to the grade of early skin reactions: the randomized EVEREST study. *Journal of Clinical Oncology*, **2012**, 30, 2861-8 | 2.2 | 99 |
| 319 | Determination of molecular marker expression can predict clinical outcome in colon carcinomas. *Clinical Cancer Research*, **2004**, 10, 3490-9 | 12.9 | 99 |
| 318 | Upfront FOLFOXIRI plus bevacizumab and reintroduction after progression versus mFOLFOX6 plus bevacizumab followed by FOLFIRI plus bevacizumab in the treatment of patients with metastatic colorectal cancer (TRIBE2): a multicentre, open-label, phase 3, randomised, controlled trial. *Lancet Oncology, The*, **2020**, 21, 497-507 | 21.7 | 98 |
| 317 | Rational bases for the development of EGFR inhibitors for cancer treatment. *International Journal of Biochemistry and Cell Biology*, **2007**, 39, 1416-31 | 5.6 | 95 |
| 316 | Combined targeting of EGFR-dependent and VEGF-dependent pathways: rationale, preclinical studies and clinical applications. *Nature Clinical Practice Oncology*, **2008**, 5, 521-30 | | 94 |
| 315 | SMO Gene Amplification and Activation of the Hedgehog Pathway as Novel Mechanisms of Resistance to Anti-Epidermal Growth Factor Receptor Drugs in Human Lung Cancer. *Clinical Cancer Research*, **2015**, 21, 4686-97 | 12.9 | 93 |
| 314 | Prognostic significance of epidermal growth factor receptor expression in colon cancer patients undergoing curative surgery. *Annals of Surgical Oncology*, **2006**, 13, 823-35 | 3.1 | 93 |
| 313 | Erlotinib in non-small cell lung cancer treatment: current status and future development. *Oncologist*, **2007**, 12, 840-9 | 5.7 | 90 |
| 312 | Elevated perioperative serum vascular endothelial growth factor levels in patients with colon carcinoma. *Cancer*, **2004**, 100, 270-8 | 6.4 | 90 |
| 311 | Synergistic effects of metformin treatment in combination with gefitinib, a selective EGFR tyrosine kinase inhibitor, in LKB1 wild-type NSCLC cell lines. *Clinical Cancer Research*, **2013**, 19, 3508-19 | 12.9 | 88 |
| 310 | Protein kinase A as target for novel integrated strategies of cancer therapy. *Annals of the New York Academy of Sciences*, **2002**, 968, 139-47 | 6.5 | 88 |
| 309 | Combination of a selective cyclooxygenase-2 inhibitor with epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 and protein kinase A antisense causes cooperative antitumor and antiangiogenic effect. *Clinical Cancer Research*, **2003**, 9, 1566-72 | 12.9 | 87 |
| 308 | The RIalpha subunit of protein kinase A (PKA) binds to Grb2 and allows PKA interaction with the activated EGF-receptor. *Oncogene*, **1997**, 14, 923-8 | 9.2 | 85 |

| | | | |
|---|---|---|---|
| 307 | Differential immunohistochemical detection of transforming growth factor alpha, amphiregulin and CRIPTO in human normal and malignant breast tissues. *International Journal of Cancer*, **1996**, 65, 51-6 | 7.5 | 84 |
| 306 | EGFR-targeted therapy. *Experimental Cell Research*, **2011**, 317, 2765-71 | 4.2 | 83 |
| 305 | Factorial phase III randomised trial of rofecoxib and prolonged constant infusion of gemcitabine in advanced non-small-cell lung cancer: the GEmcitabine-COxib in NSCLC (GECO) study. *Lancet Oncology, The*, **2007**, 8, 500-12 | 21.7 | 80 |
| 304 | Simultaneous blockage of different EGF-like growth factors results in efficient growth inhibition of human colon carcinoma xenografts. *Oncogene*, **2000**, 19, 5863-71 | 9.2 | 80 |
| 303 | Cooperative antitumor effect of multitargeted kinase inhibitor ZD6474 and ionizing radiation in glioblastoma. *Clinical Cancer Research*, **2005**, 11, 5639-44 | 12.9 | 79 |
| 302 | Antisense oligonucleotides targeting the epidermal growth factor receptor inhibit proliferation, induce apoptosis, and cooperate with cytotoxic drugs in human cancer cell lines. *International Journal of Cancer*, **2001**, 93, 172-8 | 7.5 | 79 |
| 301 | Combining targeted therapies and drugs with multiple targets in the treatment of NSCLC. *Oncologist*, **2006**, 11, 274-84 | 5.7 | 78 |
| 300 | Cancer resistance to therapies against the EGFR-RAS-RAF pathway: The role of MEK. *Cancer Treatment Reviews*, **2017**, 53, 61-69 | 14.4 | 77 |
| 299 | Cripto enhances the tyrosine phosphorylation of Shc and activates mitogen-activated protein kinase (MAPK) in mammary epithelial cells. *Journal of Biological Chemistry*, **1997**, 272, 3330-5 | 5.4 | 77 |
| 298 | Primary and acquired resistance of colorectal cancer cells to anti-EGFR antibodies converge on MEK/ERK pathway activation and can be overcome by combined MEK/EGFR inhibition. *Clinical Cancer Research*, **2014**, 20, 3775-86 | 12.9 | 76 |
| 297 | ZD1839 (IRESSA), an EGFR-selective tyrosine kinase inhibitor, enhances taxane activity in bcl-2 overexpressing, multidrug-resistant MCF-7 ADR human breast cancer cells. *International Journal of Cancer*, **2002**, 98, 463-9 | 7.5 | 76 |
| 296 | The role of EGFR inhibitors in nonsmall cell lung cancer. *Current Opinion in Oncology*, **2004**, 16, 130-5 | 4.2 | 76 |
| 295 | Intrinsic and acquired resistance to EGFR inhibitors in human cancer therapy. *Endocrine-Related Cancer*, **2005**, 12 Suppl 1, S159-71 | 5.7 | 76 |
| 294 | Novel toll-like receptor 9 agonist induces epidermal growth factor receptor (EGFR) inhibition and synergistic antitumor activity with EGFR inhibitors. *Clinical Cancer Research*, **2006**, 12, 577-83 | 12.9 | 75 |
| 293 | Anti-epidermal growth factor receptor drugs in cancer therapy. *Expert Opinion on Investigational Drugs*, **2002**, 11, 755-68 | 5.9 | 75 |
| 292 | Expression of messenger RNA for amphiregulin, heregulin, and cripto-1, three new members of the epidermal growth factor family, in human breast carcinomas. *Breast Cancer Research and Treatment* , **1995**, 35, 293-7 | 4.4 | 73 |
| 291 | Regulation by estrogen through the 5'-flanking region of the transforming growth factor alpha gene. *Molecular Endocrinology*, **1991**, 5, 1955-63 | | 73 |
| 290 | Transforming growth factor-alpha messenger RNA localization in the developing adult rat and human mammary gland by in situ hybridization. *Developmental Biology*, **1990**, 140, 123-31 | 3.1 | 72 |

| | | | |
|---|---|---|---|
| 289 | Present and future of metastatic colorectal cancer treatment: A review of new candidate targets. *World Journal of Gastroenterology*, **2017**, 23, 4675-4688 | 5.6 | 70 |
| 288 | Antitumor activity of pimasertib, a selective MEK 1/2 inhibitor, in combination with PI3K/mTOR inhibitors or with multi-targeted kinase inhibitors in pimasertib-resistant human lung and colorectal cancer cells. *International Journal of Cancer*, **2013**, 133, 2089-101 | 7.5 | 70 |
| 287 | Synergistic antitumor activity of sorafenib in combination with epidermal growth factor receptor inhibitors in colorectal and lung cancer cells. *Clinical Cancer Research*, **2010**, 16, 4990-5001 | 12.9 | 70 |
| 286 | Therapeutic value of EGFR inhibition in CRC and NSCLC: 15 years of clinical evidence. *ESMO Open*, **2016**, 1, e000088 | 6 | 69 |
| 285 | Mechanisms of resistance to anti-epidermal growth factor receptor inhibitors in metastatic colorectal cancer. *World Journal of Gastroenterology*, **2016**, 22, 6345-61 | 5.6 | 69 |
| 284 | Limits and potential of targeted sequencing analysis of liquid biopsy in patients with lung and colon carcinoma. *Oncotarget*, **2016**, 7, 66595-66605 | 3.3 | 67 |
| 283 | ALK inhibitors: a new targeted therapy in the treatment of advanced NSCLC. *Targeted Oncology*, **2013**, 8, 55-67 | 5 | 66 |
| 282 | Primary and acquired resistance to anti-EGFR targeted drugs in cancer therapy. *Differentiation*, **2007**, 75, 788-99 | 3.5 | 65 |
| 281 | Overcoming resistance to molecularly targeted anticancer therapies: Rational drug combinations based on EGFR and MAPK inhibition for solid tumours and haematologic malignancies. *Drug Resistance Updates*, **2007**, 10, 81-100 | 23.2 | 62 |
| 280 | 8-chloro-cAMP inhibits smooth muscle cell proliferation in vitro and neointima formation induced by balloon injury in vivo. *Journal of the American College of Cardiology*, **2000**, 36, 288-93 | 15.1 | 62 |
| 279 | Cooperative inhibition of renal cancer growth by anti-epidermal growth factor receptor antibody and protein kinase A antisense oligonucleotide. *Journal of the National Cancer Institute*, **1998**, 90, 1087-94 | 9.7 | 62 |
| 278 | Angiogenesis: a target for cancer therapy. *Current Pharmaceutical Design*, **2004**, 10, 11-26 | 3.3 | 61 |
| 277 | A novel MDM2 anti-sense oligonucleotide has anti-tumor activity and potentiates cytotoxic drugs acting by different mechanisms in human colon cancer. *International Journal of Cancer*, **2000**, 88, 804-9 | 7.5 | 61 |
| 276 | NM23 gene expression correlates with cell growth rate and S-phase. *International Journal of Cancer*, **1995**, 60, 837-42 | 7.5 | 60 |
| 275 | Additive effects of c-erbB-2, c-Ha-ras, and transforming growth factor-alpha genes on in vitro transformation of human mammary epithelial cells. *Molecular Carcinogenesis*, **1992**, 6, 43-52 | 5 | 60 |
| 274 | Encorafenib Plus Cetuximab as a New Standard of Care for Previously Treated V600E-Mutant Metastatic Colorectal Cancer: Updated Survival Results and Subgroup Analyses from the BEACON Study. *Journal of Clinical Oncology*, **2021**, 39, 273-284 | 2.2 | 60 |
| 273 | Guideline on the requirements of external quality assessment programs in molecular pathology. *Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin*, **2013**, 462, 27-37 | 5.1 | 59 |
| 272 | TLR9 agonist acts by different mechanisms synergizing with bevacizumab in sensitive and cetuximab-resistant colon cancer xenografts. *Proceedings of the National Academy of Sciences of the United States of America*, **2007**, 104, 12468-73 | 11.5 | 56 |

| | | | |
|---|---|---|---|
| 271 | Treatment of Elderly Patients With Non-Small-Cell Lung Cancer: Results of an International Expert Panel Meeting of the Italian Association of Thoracic Oncology. *Clinical Lung Cancer*, **2015**, 16, 325-33 | 4.9 | 55 |
| 270 | The role of amphiregulin in breast cancer. *Breast Cancer Research and Treatment*, **1995**, 33, 103-14 | 4.4 | 55 |
| 269 | Helicobacter pylori VacA toxin up-regulates vascular endothelial growth factor expression in MKN 28 gastric cells through an epidermal growth factor receptor-, cyclooxygenase-2-dependent mechanism. *Clinical Cancer Research*, **2003**, 9, 2015-21 | 12.9 | 55 |
| 268 | Efficacy of Sym004 in Patients With Metastatic Colorectal Cancer With Acquired Resistance to Anti-EGFR Therapy and Molecularly Selected by Circulating Tumor DNA Analyses: A Phase 2 Randomized Clinical Trial. *JAMA Oncology*, **2018**, 4, e175245 | 13.4 | 54 |
| 267 | Anti-tumor activity of the combination of cetuximab, an anti-EGFR blocking monoclonal antibody and ZD6474, an inhibitor of VEGFR and EGFR tyrosine kinases. *Journal of Cellular Physiology*, **2006**, 208, 344-53 | 7 | 54 |
| 266 | The tyrosine kinase inhibitor ZD6474 blocks proliferation of RET mutant medullary thyroid carcinoma cells. *Endocrine-Related Cancer*, **2011**, 18, 1-11 | 5.7 | 52 |
| 265 | Second-line treatment of advanced non-small cell lung cancer. *Journal of Thoracic Oncology*, **2008**, 3, 430-40 | 8.9 | 52 |
| 264 | EGFR in Tumor-Associated Myeloid Cells Promotes Development of Colorectal Cancer in Mice and Associates With Outcomes of Patients. *Gastroenterology*, **2017**, 153, 178-190.e10 | 13.3 | 51 |
| 263 | Primary and Acquired Resistance of Colorectal Cancer to Anti-EGFR Monoclonal Antibody Can Be Overcome by Combined Treatment of Regorafenib with Cetuximab. *Clinical Cancer Research*, **2015**, 21, 2975-83 | 12.9 | 51 |
| 262 | Metformin increases antitumor activity of MEK inhibitors through GLI1 downregulation in LKB1 positive human NSCLC cancer cells. *Oncotarget*, **2016**, 7, 4265-78 | 3.3 | 51 |
| 261 | Treatment of advanced non-small-cell lung cancer with epidermal growth factor receptor (EGFR) mutation or ALK gene rearrangement: results of an international expert panel meeting of the Italian Association of Thoracic Oncology. *Clinical Lung Cancer*, **2014**, 15, 173-81 | 4.9 | 50 |
| 260 | The use of xenograft models for the selection of cancer treatments with the EGFR as an example. *Critical Reviews in Oncology/Hematology*, **2008**, 65, 200-11 | 7 | 50 |
| 259 | HGF/MET and the Immune System: Relevance for Cancer Immunotherapy. *International Journal of Molecular Sciences*, **2018**, 19, | 6.3 | 50 |
| 258 | Involvement of growth factor receptors of the epidermal growth factor receptor family in prostate cancer development and progression to androgen independence. *Clinical Prostate Cancer*, **2003**, 2, 50-7 | | 49 |
| 257 | Epidermal growth factor receptor inhibitors in cancer treatment. *Future Oncology*, **2005**, 1, 221-34 | 3.6 | 49 |
| 256 | Triple-Negative Breast Cancers: Systematic Review of the Literature on Molecular and Clinical Features with a Focus on Treatment with Innovative Drugs. *Current Oncology Reports*, **2018**, 20, 76 | 6.3 | 48 |
| 255 | Stromal influences on transformation of human mammary epithelial cells overexpressing c-myc and SV40T. *Journal of Cellular Physiology*, **1990**, 145, 207-16 | 7 | 48 |
| 254 | Carcinogenesis as a Result of Multiple Inflammatory and Oxidative Hits: a Comprehensive Review from Tumor Microenvironment to Gut Microbiota. *Neoplasia*, **2018**, 20, 721-733 | 6.4 | 47 |

| | | | |
|---|---|---|---|
| 253 | The S492R EGFR ectodomain mutation is never detected in KRAS wild-type colorectal carcinoma before exposure to EGFR monoclonal antibodies. *Cancer Biology and Therapy*, **2013**, 14, 1143-6 | 4.6 | 47 |
| 252 | Synergistic antitumor activity of ZD6474, an inhibitor of vascular endothelial growth factor receptor and epidermal growth factor receptor signaling, with gemcitabine and ionizing radiation against pancreatic cancer. *Clinical Cancer Research*, **2006**, 12, 7099-107 | 12.9 | 47 |
| 251 | Potential treatment options after first-line chemotherapy for advanced NSCLC: maintenance treatment or early second-line?. *Oncologist*, **2009**, 14, 137-47 | 5.7 | 45 |
| 250 | AXL is an oncotarget in human colorectal cancer. *Oncotarget*, **2015**, 6, 23281-96 | 3.3 | 45 |
| 249 | HER2 Positivity Predicts Unresponsiveness to EGFR-Targeted Treatment in Metastatic Colorectal Cancer. *Oncologist*, **2019**, 24, 1395-1402 | 5.7 | 45 |
| 248 | Optimizing treatment of metastatic colorectal cancer patients with anti-EGFR antibodies: overcoming the mechanisms of cancer cell resistance. *Expert Opinion on Biological Therapy*, **2013**, 13, 241-55 | 5.4 | 44 |
| 247 | Combined targeting of epidermal growth factor receptor and MDM2 by gefitinib and antisense MDM2 cooperatively inhibit hormone-independent prostate cancer. *Clinical Cancer Research*, **2004**, 10, 4858-64 | 12.9 | 42 |
| 246 | Results of the safety run-in part of the METAL (METformin in Advanced Lung cancer) study: a multicentre, open-label phase I-II study of metformin with erlotinib in second-line therapy of patients with stage IV non-small-cell lung cancer. *ESMO Open*, **2017**, 2, e000132 | 6 | 41 |
| 245 | Correlation between efficacy and skin rash occurrence following treatment with the epidermal growth factor receptor inhibitor cetuximab: a single institution retrospective analysis. *Oncology Reports*, **2009**, 21, 1023-8 | 3.5 | 41 |
| 244 | Down-regulation of RI alpha subunit of cAMP-dependent protein kinase induces growth inhibition of human mammary epithelial cells transformed by c-Ha-ras and c-erbB-2 proto-oncogenes. *International Journal of Cancer*, **1993**, 53, 438-43 | 7.5 | 41 |
| 243 | Uptake of KRAS mutation testing in patients with metastatic colorectal cancer in Europe, Latin America and Asia. *Targeted Oncology*, **2011**, 6, 133-45 | 5 | 40 |
| 242 | EGF-related peptides in the pathophysiology of the mammary gland. *Journal of Mammary Gland Biology and Neoplasia*, **1997**, 2, 143-51 | 2.4 | 40 |
| 241 | Detection of KRAS mutations in colorectal carcinoma patients with an integrated PCR/sequencing and real-time PCR approach. *Pharmacogenomics*, **2010**, 11, 1169-79 | 2.6 | 39 |
| 240 | Erlotinib: an EGF receptor tyrosine kinase inhibitor in non-small-cell lung cancer treatment. *Expert Review of Respiratory Medicine*, **2008**, 2, 167-78 | 3.8 | 39 |
| 239 | Site-selective 8-chloroadenosine 3',5'-cyclic monophosphate inhibits transformation and transforming growth factor alpha production in Ki-ras-transformed rat fibroblasts. *FEBS Letters*, **1989**, 242, 363-7 | 3.8 | 39 |
| 238 | Treatment outcome according to tumor RAS mutation status in OPUS study patients with metastatic colorectal cancer (mCRC) randomized to FOLFOX4 with/without cetuximab.. *Journal of Clinical Oncology*, **2014**, 32, 3505-3505 | 2.2 | 38 |
| 237 | Receptor tyrosine kinase-dependent PI3K activation is an escape mechanism to vertical suppression of the EGFR/RAS/MAPK pathway in KRAS-mutated human colorectal cancer cell lines. *Journal of Experimental and Clinical Cancer Research*, **2019**, 38, 41 | 12.8 | 37 |
| 236 | Sequence-dependent inhibition of human colon cancer cell growth and of prosurvival pathways by oxaliplatin in combination with ZD6474 (Zactima), an inhibitor of VEGFR and EGFR tyrosine kinases. *Molecular Cancer Therapeutics*, **2006**, 5, 1883-94 | 6.1 | 37 |

| | | | |
|---|---|---|---|
| 235 | Combined targeted inhibition of bcl-2, bcl-XL, epidermal growth factor receptor, and protein kinase A type I causes potent antitumor, apoptotic, and antiangiogenic activity. *Clinical Cancer Research*, **2003**, 9, 866-71 | 12.9 | 37 |
| 234 | Targeting vascular endothelial growth factor receptor-1 and -3 with cediranib (AZD2171): effects on migration and invasion of gastrointestinal cancer cell lines. *Molecular Cancer Therapeutics*, **2009**, 8, 2546-58 | 6.1 | 36 |
| 233 | Preclinical activity of the rational combination of selumetinib (AZD6244) in combination with vorinostat in KRAS-mutant colorectal cancer models. *Clinical Cancer Research*, **2012**, 18, 1051-62 | 12.9 | 36 |
| 232 | Investigation of two dosing schedules of vandetanib (ZD6474), an inhibitor of vascular endothelial growth factor receptor and epidermal growth factor receptor signaling, in combination with irinotecan in a human colon cancer xenograft model. *Clinical Cancer Research*, **2007**, 13, 6450-8 | 12.9 | 36 |
| 231 | Clinical management of advanced gastric cancer: the role of new molecular drugs. *World Journal of Gastroenterology*, **2014**, 20, 14537-58 | 5.6 | 36 |
| 230 | Vascular endothelial growth factor in pleural fluid for differential diagnosis of benign and malignant origin and its clinical applications. *Interactive Cardiovascular and Thoracic Surgery*, **2011**, 12, 420-4 | 1.8 | 35 |
| 229 | Pertuzumab and trastuzumab emtansine in patients with HER2-amplified metastatic colorectal cancer: the phase II HERACLES-B trial. *ESMO Open*, **2020**, 5, e000911 | 6 | 35 |
| 228 | Role and targeting of anaplastic lymphoma kinase in cancer. *Molecular Cancer*, **2018**, 17, 30 | 42.1 | 34 |
| 227 | Current status of targeted therapies in advanced gastric cancer. *Expert Opinion on Therapeutic Targets*, **2012**, 16 Suppl 2, S29-34 | 6.4 | 34 |
| 226 | Improving outcomes in colorectal cancer: where do we go from here?. *European Journal of Cancer*, **2013**, 49, 2476-85 | 7.5 | 34 |
| 225 | Antitumor activity of sorafenib in human cancer cell lines with acquired resistance to EGFR and VEGFR tyrosine kinase inhibitors. *PLoS ONE*, **2011**, 6, e28841 | 3.7 | 34 |
| 224 | Implication of the Hedgehog pathway in hepatocellular carcinoma. *World Journal of Gastroenterology*, **2017**, 23, 4330-4340 | 5.6 | 33 |
| 223 | Regorafenib plus modified FOLFOX6 as first-line treatment of metastatic colorectal cancer: A phase II trial. *European Journal of Cancer*, **2015**, 51, 942-9 | 7.5 | 32 |
| 222 | p27 downregulation and metallothionein overexpression in gastric cancer patients are associated with a poor survival rate. *Journal of Surgical Oncology*, **2006**, 93, 241-52 | 2.8 | 32 |
| 221 | Antisense strategies targeting protein kinase C: preclinical and clinical development. *Seminars in Oncology*, **2003**, 30, 26-31 | 5.5 | 32 |
| 220 | Treatment outcome according to tumor RAS mutation status in CRYSTAL study patients with metastatic colorectal cancer (mCRC) randomized to FOLFIRI with/without cetuximab.. *Journal of Clinical Oncology*, **2014**, 32, 3506-3506 | 2.2 | 32 |
| 219 | Vascular endothelial growth factor and neo-angiogenesis in H. pylori gastritis in humans. *Journal of Pathology*, **2005**, 207, 277-84 | 9.4 | 31 |
| 218 | Chemosensitization by antisense oligonucleotides targeting MDM2. *Current Cancer Drug Targets*, **2005**, 5, 51-6 | 2.8 | 31 |

| | | | |
|---|---|---|---|
| 217 | Amphiregulin anti-sense oligodeoxynucleotides inhibit growth and transformation of a human colon carcinoma cell line. *International Journal of Cancer*, **1995**, 62, 762-6 | 7.5 | 31 |
| 216 | Trifluridine/Tipiracil (TAS-102) in Refractory Metastatic Colorectal Cancer: A Multicenter Register in the Frame of the Italian Compassionate Use Program. *Oncologist*, **2018**, 23, 1178-1187 | 5.7 | 31 |
| 215 | EPHA2 Is a Predictive Biomarker of Resistance and a Potential Therapeutic Target for Improving Antiepidermal Growth Factor Receptor Therapy in Colorectal Cancer. *Molecular Cancer Therapeutics* , **2019**, 18, 845-855 | 6.1 | 30 |
| 214 | Early Triple Negative Breast Cancer: Conventional Treatment and Emerging Therapeutic Landscapes. *Cancers*, **2020**, 12, | 6.6 | 30 |
| 213 | ALK inhibitors and advanced non-small cell lung cancer (review). *International Journal of Oncology*, **2014**, 45, 499-508 | 4.4 | 30 |
| 212 | Anti-sense oligonucleotides directed against EGF-related growth factors enhance anti-proliferative effect of conventional anti-tumor drugs in human colon-cancer cells. *International Journal of Cancer* , **1997**, 73, 277-82 | 7.5 | 30 |
| 211 | Zoledronic acid cooperates with a cyclooxygenase-2 inhibitor and gefitinib in inhibiting breast and prostate cancer. *Endocrine-Related Cancer*, **2005**, 12, 1051-8 | 5.7 | 30 |
| 210 | EGF-related peptides are involved in the proliferation and survival of MDA-MB-468 human breast carcinoma cells. *International Journal of Cancer*, **1999**, 80, 589-94 | 7.5 | 30 |
| 209 | Over-expression of the epidermal growth factor receptor in human breast cancer cells fails to induce an estrogen-independent phenotype. *International Journal of Cancer*, **1990**, 46, 712-8 | 7.5 | 30 |
| 208 | Synergistic anti-proliferative and pro-apoptotic activity of combined therapy with bortezomib, a proteasome inhibitor, with anti-epidermal growth factor receptor (EGFR) drugs in human cancer cells. *Journal of Cellular Physiology*, **2008**, 216, 698-707 | 7 | 29 |
| 207 | Infection with a transforming growth factor alpha anti-sense retroviral expression vector reduces the in vitro growth and transformation of a human colon cancer cell line. *International Journal of Cancer*, **1993**, 54, 952-8 | 7.5 | 29 |
| 206 | Awareness, Understanding, and Adoption of Precision Medicine to Deliver Personalized Treatment for Patients With Cancer: A Multinational Survey Comparison of Physicians and Patients. *Oncologist*, **2016**, 21, 292-300 | 5.7 | 28 |
| 205 | ZD6474, an inhibitor of VEGFR and EGFR tyrosine kinase activity in combination with radiotherapy. *International Journal of Radiation Oncology Biology Physics*, **2006**, 64, 33-7 | 4 | 28 |
| 204 | HER2 signaling and resistance to the anti-EGFR monoclonal antibody cetuximab: a further step toward personalized medicine for patients with colorectal cancer. *Cancer Discovery*, **2011**, 1, 472-4 | 24.4 | 27 |
| 203 | An international, multicenter, randomized phase III study of first-line erlotinib followed by second-line cisplatin/gemcitabine versus first-line cisplatin/gemcitabine followed by second-line erlotinib in advanced non-small-cell lung cancer: treatment rationale and protocol dynamics of the TORCH trial. *Clinical Lung Cancer*, **2008**, 9, 235-8 | 4.9 | 27 |
| 202 | Role of the cripto (EGF-CFC) family in embryogenesis and cancer. *Growth Factors*, **2004**, 22, 133-9 | 1.6 | 27 |
| 201 | BEVERLY: Rationale and Design of a Randomized Open-Label Phase III Trial Comparing Bevacizumab Plus Erlotinib Versus Erlotinib Alone as First-Line Treatment of Patients With EGFR-Mutated Advanced Nonsquamous Non-Small-Cell Lung Cancer. *Clinical Lung Cancer*, **2016**, 17, 461-465 | 4.9 | 27 |
| 200 | Cisplatin-Based First-Line Treatment of Elderly Patients With Advanced Non-Small-Cell Lung Cancer: Joint Analysis of MILES-3 and MILES-4 Phase III Trials. *Journal of Clinical Oncology*, **2018**, 36, 2585-2592 | 2.2 | 27 |

| | | | |
|---|---|---|---|
| 199 | Incidence and risk factors of early HCC occurrence in HCV patients treated with direct acting antivirals: a prospective multicentre study. *Journal of Translational Medicine*, **2019**, 17, 292 | 8.5 | 26 |
| 198 | Metabolomic approach for a rapid identification of natural products with cytotoxic activity against human colorectal cancer cells. *Scientific Reports*, **2018**, 8, 5309 | 4.9 | 26 |
| 197 | Expression of Wnt5a is downregulated by extracellular matrix and mutated c-Ha-ras in the human mammary epithelial cell line MCF-10A. *Biochemical and Biophysical Research Communications*, **1997**, 239, 911-7 | 3.4 | 26 |
| 196 | Trying to compose the puzzle with all the pieces: epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer. *Journal of Cellular Physiology*, **2005**, 205, 355-63 | 7 | 26 |
| 195 | Resistance to taxanes is induced by c-erbB-2 overexpression in human MCF-10A mammary epithelial cells and is blocked by combined treatment with an antisense oligonucleotide targeting type I protein kinase A. *International Journal of Cancer*, **2000**, 85, 710-5 | 7.5 | 26 |
| 194 | KRAS mutations testing in colorectal carcinoma patients in Italy: from guidelines to external quality assessment. *PLoS ONE*, **2011**, 6, e29146 | 3.7 | 26 |
| 193 | Efficacy of continuous EGFR-inhibition and role of Hedgehog in EGFR acquired resistance in human lung cancer cells with activating mutation of EGFR. *Oncotarget*, **2017**, 8, 23020-23032 | 3.3 | 26 |
| 192 | Antitumor activity of ZD6126, a novel vascular-targeting agent, is enhanced when combined with ZD1839, an epidermal growth factor receptor tyrosine kinase inhibitor, and potentiates the effects of radiation in a human non-small cell lung cancer xenograft model. *Molecular Cancer Therapeutics*, **2004**, 3, 977-83 | 6.1 | 26 |
| 191 | Epidermal growth factor receptor tyrosine kinase inhibitors in late stage clinical trials. *Expert Opinion on Emerging Drugs*, **2003**, 8, 501-14 | 3.7 | 25 |
| 190 | What's New in Gastric Cancer: The Therapeutic Implications of Molecular Classifications and Future Perspectives. *International Journal of Molecular Sciences*, **2018**, 19, | 6.3 | 25 |
| 189 | Antitumor activity of ZD6474, a vascular endothelial growth factor-2 and epidermal growth factor receptor small molecule tyrosine kinase inhibitor, in combination with SC-236, a cyclooxygenase-2 inhibitor. *Clinical Cancer Research*, **2005**, 11, 1268-76 | 12.9 | 25 |
| 188 | Perioperative Treatment in Resectable Gastric Cancer: Current Perspectives and Future Directions. *Cancers*, **2019**, 11, | 6.6 | 24 |
| 187 | Sequential HER2 blockade as effective therapy in chemorefractory, HER2 gene-amplified, RAS wild-type, metastatic colorectal cancer: learning from a clinical case. *ESMO Open*, **2018**, 3, e000299 | 6 | 24 |
| 186 | Rationale and design of MILES-3 and MILES-4 studies: two randomized phase 3 trials comparing single-agent chemotherapy versus cisplatin-based doublets in elderly patients with advanced non--small-cell lung cancer. *Clinical Lung Cancer*, **2014**, 15, 166-70 | 4.9 | 24 |
| 185 | Emerging VEGF-receptor inhibitors for colorectal cancer. *Expert Opinion on Emerging Drugs*, **2013**, 18, 25-37 | 3.7 | 24 |
| 184 | Role of HGF-MET Signaling in Primary and Acquired Resistance to Targeted Therapies in Cancer. *Biomedicines*, **2014**, 2, 345-358 | 4.8 | 24 |
| 183 | Phase II randomized study of vandetanib plus gemcitabine or gemcitabine plus placebo as first-line treatment of advanced non-small-cell lung cancer in elderly patients. *Journal of Thoracic Oncology*, **2014**, 9, 733-7 | 8.9 | 24 |
| 182 | Antitumor activity of bortezomib in human cancer cells with acquired resistance to anti-epidermal growth factor receptor tyrosine kinase inhibitors. *Lung Cancer*, **2011**, 71, 283-90 | 5.9 | 24 |

| | | | |
|---|---|---|---|
| 181 | Response of normal and oncogene-transformed human mammary epithelial cells to transforming growth factor beta 1 (TGF-beta 1): lack of growth-inhibitory effect on cells expressing the simian virus 40 large-T antigen. *International Journal of Cancer*, **1994**, 56, 736-42 | 7.5 | 24 |
| 180 | Trastuzumab and lapatinib in HER2-amplified metastatic colorectal cancer patients (mCRC): The HERACLES trial.. *Journal of Clinical Oncology*, **2015**, 33, 3508-3508 | 2.2 | 23 |
| 179 | Safety and efficacy of sorafenib in patients with advanced hepatocellular carcinoma and Child-Pugh A or B cirrhosis. *Oncology Letters*, **2015**, 9, 1628-1632 | 2.6 | 22 |
| 178 | Long-term Clinical Outcome of Trastuzumab and Lapatinib for HER2-positive Metastatic Colorectal Cancer. *Clinical Colorectal Cancer*, **2020**, 19, 256-262.e2 | 3.8 | 22 |
| 177 | Metformin in lung cancer: rationale for a combination therapy. *Expert Opinion on Investigational Drugs*, **2013**, 22, 1401-9 | 5.9 | 22 |
| 176 | Medical treatment of small cell lung cancer: state of the art and new development. *Expert Opinion on Pharmacotherapy*, **2013**, 14, 2019-31 | 4 | 22 |
| 175 | Sequence-dependent, synergistic antiproliferative and proapoptotic effects of the combination of cytotoxic drugs and enzastaurin, a protein kinase Cbeta inhibitor, in non-small cell lung cancer cells. *Molecular Cancer Therapeutics*, **2008**, 7, 1698-707 | 6.1 | 22 |
| 174 | Differential growth factor expression in transformed mouse NIH-3T3 cells. *Journal of Cellular Biochemistry*, **1990**, 42, 45-57 | 4.7 | 22 |
| 173 | Type III or allosteric kinase inhibitors for the treatment of non-small cell lung cancer. *Expert Opinion on Investigational Drugs*, **2014**, 23, 809-21 | 5.9 | 21 |
| 172 | A randomized phase II study of sorafenib/gemcitabine or sorafenib/erlotinib for advanced non-small-cell lung cancer in elderly patients or patients with a performance status of 2: treatment rationale and protocol dynamics. *Clinical Lung Cancer*, **2007**, 8, 396-8 | 4.9 | 21 |
| 171 | Phosphatidylinositol 3-kinase (PI3K)/AKT axis blockade with taselisib or ipatasertib enhances the efficacy of anti-microtubule drugs in human breast cancer cells. *Oncotarget*, **2017**, 8, 76479-76491 | 3.3 | 20 |
| 170 | Maintenance treatment of advanced non-small-cell lung cancer: results of an international expert panel meeting of the Italian association of thoracic oncology. *Lung Cancer*, **2012**, 76, 269-79 | 5.9 | 20 |
| 169 | Combined targeted therapies in non-small cell lung cancer: a winner strategy?. *Current Opinion in Oncology*, **2007**, 19, 98-102 | 4.2 | 20 |
| 168 | Antisense targeting protein kinase A type I as a drug for integrated strategies of cancer therapy. *Annals of the New York Academy of Sciences*, **2003**, 1002, 236-43 | 6.5 | 20 |
| 167 | Regorafenib in combination with silybin as a novel potential strategy for the treatment of metastatic colorectal cancer. *Oncotarget*, **2017**, 8, 68305-68316 | 3.3 | 20 |
| 166 | How we treat metastatic colorectal cancer. *ESMO Open*, **2020**, 4, e000813 | 6 | 20 |
| 165 | Activity and molecular targets of pioglitazone via blockade of proliferation, invasiveness and bioenergetics in human NSCLC. *Journal of Experimental and Clinical Cancer Research*, **2019**, 38, 178 | 12.8 | 19 |
| 164 | Antitumor Efficacy of Dual Blockade of EGFR Signaling by Osimertinib in Combination With Selumetinib or Cetuximab in Activated EGFR Human NCLC Tumor Models. *Journal of Thoracic Oncology*, **2018**, 13, 810-820 | 8.9 | 19 |

| | | | |
|---|---|---|---|
| 163 | Clinical outcome and molecular characterisation of chemorefractory metastatic colorectal cancer patients with long-term efficacy of regorafenib treatment. *ESMO Open*, **2017**, 2, e000177 | 6 | 19 |
| 162 | Dual MET and SMO Negative Modulators Overcome Resistance to EGFR Inhibitors in Human Nonsmall Cell Lung Cancer. *Journal of Medicinal Chemistry*, **2017**, 60, 7447-7458 | 8.3 | 19 |
| 161 | Detection of erbB2 copy number variations in plasma of patients with esophageal carcinoma. *BMC Cancer*, **2011**, 11, 126 | 4.8 | 19 |
| 160 | Cetuximab and gemcitabine in elderly or adult PS2 patients with advanced non-small-cell lung cancer: The cetuximab in advanced lung cancer (CALC1-E and CALC1-PS2) randomized phase II trials. *Lung Cancer*, **2010**, 67, 86-92 | 5.9 | 19 |
| 159 | Induction of multidrug resistance (MDR) by transfection of MCF-10A cell line with c-Ha-ras and c-erbB-2 oncogenes. *International Journal of Cancer*, **1994**, 59, 208-11 | 7.5 | 19 |
| 158 | Use of Rituximab in NHL Malt Type Pregnant in I□Trimester for Two Times. *Open Medicine (Poland)*, **2019**, 14, 757-760 | 2.2 | 19 |
| 157 | Resistance to anti-epidermal growth factor receptor in metastatic colorectal cancer: What does still need to be addressed?. *Cancer Treatment Reviews*, **2020**, 86, 102023 | 14.4 | 19 |
| 156 | Cancer- and Non-cancer Related Chronic Pain: From the Physiopathological Basics to Management. *Open Medicine (Poland)*, **2019**, 14, 761-766 | 2.2 | 18 |
| 155 | Beyond bevacizumab: new anti-VEGF strategies in colorectal cancer. *Expert Opinion on Investigational Drugs*, **2012**, 21, 949-59 | 5.9 | 18 |
| 154 | A randomized phase II study of pemetrexed or RAD001 as second-line treatment of advanced non-small-cell lung cancer in elderly patients: treatment rationale and protocol dynamics. *Clinical Lung Cancer*, **2007**, 8, 568-71 | 4.9 | 18 |
| 153 | Transfection with a CRIPTO anti-sense plasmid suppresses endogenous CRIPTO expression and inhibits transformation in a human embryonal carcinoma cell line. *International Journal of Cancer*, **1996**, 66, 538-43 | 7.5 | 18 |
| 152 | FCGR polymorphisms and cetuximab efficacy in chemorefractory metastatic colorectal cancer: an international consortium study. *Gut*, **2015**, 64, 921-8 | 19.2 | 17 |
| 151 | Kisspeptin and Cancer: Molecular Interaction, Biological Functions, and Future Perspectives. *Frontiers in Endocrinology*, **2018**, 9, 115 | 5.7 | 17 |
| 150 | Clinical Practice Use of Liquid Biopsy to Identify RAS/BRAF Mutations in Patients with Metastatic Colorectal Cancer (mCRC): A Single Institution Experience. *Cancers*, **2019**, 11, | 6.6 | 17 |
| 149 | Quality of life analysis of TORCH, a randomized trial testing first-line erlotinib followed by second-line cisplatin/gemcitabine chemotherapy in advanced non-small-cell lung cancer. *Journal of Thoracic Oncology*, **2012**, 7, 1830-1844 | 8.9 | 17 |
| 148 | Perspectives in adjuvant therapy of gastric cancer. *Oncology*, **2009**, 77 Suppl 1, 38-42 | 3.6 | 17 |
| 147 | Resistance mechanisms of tumour cells to EGFR inhibitors. *Clinical and Translational Oncology*, **2009** , 11, 270-5 | 3.6 | 17 |
| 146 | Antiangiogenic drugs in non-small cell lung cancer treatment. *Current Opinion in Oncology*, **2006**, 18, 151-52 | 3.5 | 17 |

| | | | |
|---|---|---|---|
| 145 | Transformation of mouse mammary epithelial cells with the Ha-ras but not with the neu oncogene results in a gene dosage-dependent increase in transforming growth factor-alpha production. *FEBS Letters*, **1989**, 250, 474-8 | 3.8 | 17 |
| 144 | Growth of cells on a perfluorocarbon-medium interphase: a quantitative assay for anchorage-independent cell growth. *In Vitro Cellular & Developmental Biology*, **1988**, 24, 71-8 | | 17 |
| 143 | Primary Cutaneous DLBCL Non-GCB Type: Challenges of a Rare Case. *Open Medicine (Poland)*, **2020**, 15, 119-125 | 2.2 | 17 |
| 142 | A multicenter, open-label phase II study of metformin with erlotinib in second-line therapy of stage IV non-small-cell lung cancer patients: treatment rationale and protocol dynamics of the METAL trial. *Clinical Lung Cancer*, **2015**, 16, 57-9 | 4.9 | 16 |
| 141 | Weekly chemotherapy with cisplatin and paclitaxel and concurrent radiation therapy as preoperative treatment in locally advanced esophageal cancer: a phase II study. *Cancer Investigation*, **2010**, 28, 820-7 | 2.1 | 16 |
| 140 | The potential role of pharmacogenomic and genomic in the adjuvant treatment of early stage non small cell lung cancer. *Current Genomics*, **2008**, 9, 252-62 | 2.6 | 16 |
| 139 | HER2 amplification as a molecular bait for trastuzumab-emtansine (T-DM1) precision chemotherapy to overcome anti-HER2 resistance in HER2 positive metastatic colorectal cancer: The HERACLES-RESCUE trial.. *Journal of Clinical Oncology*, **2016**, 34, TPS774-TPS774 | 2.2 | 16 |
| 138 | Novel investigational drugs for gastric cancer. *Expert Opinion on Investigational Drugs*, **2009**, 18, 945-55 | 5.9 | 15 |
| 137 | Genomic Profiling of Wild-Type Metastatic Colorectal Cancer Patients Reveals Novel Mutations in Genes Potentially Associated with Resistance to Anti-EGFR Agents. *Cancers*, **2019**, 11, | 6.6 | 14 |
| 136 | Adaptation of international guidelines for metastatic colorectal cancer: an asian consensus. *Clinical Colorectal Cancer*, **2014**, 13, 145-55 | 3.8 | 14 |
| 135 | Adjuvant chemoradiotherapy in patients with stage III or IV radically resected gastric cancer: a pilot study. *Archives of Surgery*, **2010**, 145, 233-8 | | 14 |
| 134 | Differential Diagnosis: Retroperitoneal Fibrosis and Oncological Diseases. *Open Medicine (Poland)*, **2018**, 15, 22-26 | 2.2 | 14 |
| 133 | Optimal treatment strategy for metastatic melanoma patients harboring mutations. *Therapeutic Advances in Medical Oncology*, **2020**, 12, 1758835920925219 | 5.4 | 13 |
| 132 | Maintenance Treatment with Cetuximab and BAY86-9766 Increases Antitumor Efficacy of Irinotecan plus Cetuximab in Human Colorectal Cancer Xenograft Models. *Clinical Cancer Research*, **2015**, 21, 4153-64 | 12.9 | 13 |
| 131 | Unhealthy diets: a common soil for the association of metabolic syndrome and cancer. *Endocrine*, **2014**, 46, 39-42 | 4 | 13 |
| 130 | Cetuximab in the treatment of colorectal cancer. *Future Oncology*, **2005**, 1, 173-81 | 3.6 | 13 |
| 129 | Cetuximab in advanced non-small cell lung cancer (NSCLC): the showdown?. *Journal of Thoracic Disease*, **2014**, 6, 578-80 | 2.6 | 13 |
| 128 | Cetuximab Rechallenge Plus Avelumab in Pretreated Patients With RAS Wild-type Metastatic Colorectal Cancer: The Phase 2 Single-Arm Clinical CAVE Trial. *JAMA Oncology*, **2021**, 7, 1529-1535 | 13.4 | 13 |

| | | | |
|---|---|---|---|
| 127 | Combined blockade of MEK and PI3KCA as an effective antitumor strategy in HER2 gene amplified human colorectal cancer models. *Journal of Experimental and Clinical Cancer Research*, **2019**, 38, 236 | 12.8 | 12 |
| 126 | The c-Met inhibitors: a new class of drugs in the battle against advanced nonsmall-cell lung cancer. *Current Pharmaceutical Design*, **2012**, 18, 6155-68 | 3.3 | 12 |
| 125 | Flow-cytometric detection of the RI alpha subunit of type I cAMP-dependent protein kinase in human cells. *Cytometry*, **1994**, 15, 73-9 | | 12 |
| 124 | Updated results of the BEACON CRC safety lead-in: Encorafenib (ENCO) + binimetinib (BINI) + cetuximab (CETUX) for BRAFV600E-mutant metastatic colorectal cancer (mCRC).. *Journal of Clinical Oncology*, **2019**, 37, 688-688 | 2.2 | 12 |
| 123 | Induction of natural killer antibody-dependent cell cytotoxicity and of clinical activity of cetuximab plus avelumab in non-small cell lung cancer. *ESMO Open*, **2020**, 5, e000753 | 6 | 12 |
| 122 | Ex vivo lung cancer spheroids resemble treatment response of a patient with NSCLC to chemotherapy and immunotherapy: case report and translational study. *ESMO Open*, **2019**, 4, e000536 | 6 | 12 |
| 121 | ICECREAM: randomised phase II study of cetuximab alone or in combination with irinotecan in patients with metastatic colorectal cancer with either KRAS, NRAS, BRAF and PI3KCA wild type, or G13D mutated tumours. *BMC Cancer*, **2016**, 16, 339 | 4.8 | 11 |
| 120 | Therapeutic efficacy of SYM004, a mixture of two anti-EGFR antibodies in human colorectal cancer with acquired resistance to cetuximab and MET activation. *Oncotarget*, **2017**, 8, 67592-67604 | 3.3 | 11 |
| 119 | Atypical haemolytic-uraemic syndrome in patient with metastatic colorectal cancer treated with fluorouracil and oxaliplatin: a case report and a review of literature. *ESMO Open*, **2019**, 4, e000551 | 6 | 11 |
| 118 | Head and neck cancer: the role of anti-EGFR agents in the era of immunotherapy. *Therapeutic Advances in Medical Oncology*, **2021**, 13, 1758835920949418 | 5.4 | 11 |
| 117 | Immunotherapy in advanced Non-Small Cell Lung Cancer patients with poor performance status: The role of clinical-pathological variables and inflammatory biomarkers. *Lung Cancer*, **2021**, 152, 165-173 | 5.9 | 11 |
| 116 | Emerging drugs targeting PD-1 and PD-L1: reality or hope?. *Expert Opinion on Emerging Drugs*, **2014**, 19, 557-69 | 3.7 | 10 |
| 115 | Emerging mitotic inhibitors for non-small cell carcinoma. *Expert Opinion on Emerging Drugs*, **2013**, 18, 97-107 | 3.7 | 10 |
| 114 | Targeted approach to metastatic colorectal cancer: what comes beyond epidermal growth factor receptor antibodies and bevacizumab?. *Therapeutic Advances in Medical Oncology*, **2013**, 5, 51-72 | 5.4 | 10 |
| 113 | Conversion chemotherapy followed by hepatic resection in colorectal cancer with initially unresectable liver-limited metastases. *Oncology Reports*, **2013**, 30, 2992-8 | 3.5 | 10 |
| 112 | Optimizing Anti-EGFR Therapy in Colorectal Cancer. *Clinical Cancer Research*, **2015**, 21, 5415-6 | 12.9 | 9 |
| 111 | Hepatoid carcinoma colliding with a liposarcoma of the left colon serosa presenting as an abdominal mass. *World Journal of Surgical Oncology*, **2007**, 5, 42 | 3.4 | 9 |
| 110 | In vitro expansion of human breast cancer epithelial and mesenchymal stromal cells: optimization of a coculture model for personalized therapy approaches. *Molecular Cancer Therapeutics*, **2007**, 6, 3091-100 | 6.1 | 9 |

| | | | |
|---|---|---|---|
| 109 | AXL is a predictor of poor survival and of resistance to anti-EGFR therapy in RAS wild-type metastatic colorectal cancer. *European Journal of Cancer*, **2020**, 138, 1-10 | 7.5 | 9 |
| 108 | Clinical epigenetics settings for cancer and cardiovascular diseases: real-life applications of network medicine at the bedside. *Clinical Epigenetics*, **2021**, 13, 66 | 7.7 | 9 |
| 107 | Avelumab and cetuximab as a therapeutic combination: An overview of scientific rationale and current clinical trials in cancer. *Cancer Treatment Reviews*, **2021**, 97, 102172 | 14.4 | 9 |
| 106 | Epidermal growth factor receptor (EGFR) inhibitors in cancer therapy. *Progress in Drug Research Fortschritte Der Arzneimittelforschung Progres Des Recherches Pharmaceutiques*, **2005**, 63, 93-114 | | 9 |
| 105 | Understanding the mechanisms of action of EGFR inhibitors in NSCLC: what we know and what we do not know. *Lung Cancer*, **2003**, 41 Suppl 1, S15-22 | 5.9 | 8 |
| 104 | Career opportunities and benefits for young oncologists in the European Society for Medical Oncology (ESMO). *ESMO Open*, **2016**, 1, e000107 | 6 | 8 |
| 103 | Clinical management of metastatic colorectal cancer in the era of precision medicine.. *Ca-A Cancer Journal for Clinicians*, **2022**, | 220.7 | 8 |
| 102 | Urtica dioica L. inhibits proliferation and enhances cisplatin cytotoxicity in NSCLC cells via Endoplasmic Reticulum-stress mediated apoptosis. *Scientific Reports*, **2019**, 9, 4986 | 4.9 | 7 |
| 101 | Dual anti-HER2 treatment of patients with HER2-positive metastatic colorectal cancer: The HERACLES trial (HER2 Amplification for Colo-rectaL Cancer Enhanced Stratification).. *Journal of Clinical Oncology*, **2013**, 31, TPS3648-TPS3648 | 2.2 | 7 |
| 100 | Biomarker analysis of the phase 3 TORCH trial for first line erlotinib chemotherapy in advanced non-small cell lung cancer patients. *Oncotarget*, **2017**, 8, 57528-57536 | 3.3 | 7 |
| 99 | Nivolumab in Heavily Pretreated Metastatic Gastric Cancer Patients: Real-Life Data from a Western Population. *OncoTargets and Therapy*, **2020**, 13, 867-876 | 4.4 | 7 |
| 98 | Biomarker-Guided Anti-Egfr Rechallenge Therapy in Metastatic Colorectal Cancer. *Cancers*, **2021**, 13, | 6.6 | 7 |
| 97 | Epigenetic mechanisms underlying prostate cancer radioresistance. *Clinical Epigenetics*, **2021**, 13, 125 | 7.7 | 7 |
| 96 | Pancreatic Cancer Molecular Classifications: From Bulk Genomics to Single Cell Analysis. *International Journal of Molecular Sciences*, **2020**, 21, | 6.3 | 7 |
| 95 | 30 Immunotherapy in advanced NSCLC-from the 'tsunami' of therapeutic knowledge to a clinical practice algorithm: results from an international expert panel meeting of the Italian Association of Thoracic Oncology (AIOT). *ESMO Open*, **2018**, 3, e000298 | 6 | 7 |
| 94 | The role of ras gene expression and transforming growth factor alpha production in the etiology and progression of rodent and human breast cancer. *Cancer Treatment and Research*, **1991**, 53, 107-57 | 3.5 | 7 |
| 93 | Macrophage Migration Inhibitory Factor Is a Molecular Determinant of the Anti-EGFR Monoclonal Antibody Cetuximab Resistance in Human Colorectal Cancer Cells. *Cancers*, **2019**, 11, | 6.6 | 6 |
| 92 | PARP Inhibitors in First-Line Therapy of Ovarian Cancer: Are There Any Doubts?. *Frontiers in Oncology*, **2020**, 10, 782 | 5.3 | 6 |

| | | | |
|---|---|---|---|
| 91 | Feasibility of next-generation sequencing in clinical practice: results of a pilot study in the Department of Precision Medicine at the University of Campania 'Luigi Vanvitelli'. *ESMO Open*, **2020**, 5, | 6 | 6 |
| 90 | Second-Line Treatment Options in Non-Small-Cell Lung Cancer: Report From an International Experts Panel Meeting of the Italian Association of Thoracic Oncology. *Clinical Lung Cancer*, **2018**, 19, 301-314 | 4.9 | 6 |
| 89 | Phase II study of avelumab in combination with cetuximab in pre-treated RAS wild-type metastatic colorectal cancer patients: CAVE (cetuximab-avelumab) Colon.. *Journal of Clinical Oncology*, **2019**, 37, TPS731-TPS731 | 2.2 | 6 |
| 88 | Genomic Profile and BRCA-1 Promoter Methylation Status in BRCA Mutated Ovarian Cancer: New Insights in Predictive Biomarkers of Olaparib Response. *Frontiers in Oncology*, **2019**, 9, 1289 | 5.3 | 6 |
| 87 | Vulnerability to low-dose combination of irinotecan and niraparib in ATM-mutated colorectal cancer. *Journal of Experimental and Clinical Cancer Research*, **2021**, 40, 15 | 12.8 | 6 |
| 86 | Efficacy of a triplet and doublet-based chemotherapy as first-line therapy in patients with HER2-negative metastatic gastric cancer: a retrospective analysis from the clinical practice. *Medical Oncology*, **2017**, 34, 186 | 3.7 | 5 |
| 85 | Antitumor efficacy of triple monoclonal antibody inhibition of epidermal growth factor receptor (EGFR) with MM151 in EGFR-dependent and in cetuximab-resistant human colorectal cancer cells. *Oncotarget*, **2017**, 8, 82773-82783 | 3.3 | 5 |
| 84 | Preoperative treatment of locally advanced esophageal carcinoma (Review). *International Journal of Oncology*, **2013**, 43, 1745-53 | 4.4 | 5 |
| 83 | Critical appraisal of the use of regorafenib in the management of colorectal cancer. *Cancer Management and Research*, **2013**, 5, 49-55 | 3.6 | 5 |
| 82 | Down-regulation of type I protein kinase A by transfection of human breast cancer cells with an epidermal growth factor receptor antisense expression vector. *Breast Cancer Research and Treatment*, **1998**, 47, 57-62 | 4.4 | 5 |
| 81 | Mechanisms of resistance to EGFR inhibitors. *Targeted Oncology*, **2007**, 2, 31-37 | 5 | 5 |
| 80 | Antitumor efficacy of Kisspeptin in human malignant mesothelioma cells. *Oncotarget*, **2018**, 9, 19273-19282 | 5.2 | 5 |
| 79 | Cancer Treatment-Induced Bone Loss (CTIBL): State of the Art and Proper Management in Breast Cancer Patients on Endocrine Therapy. *Current Treatment Options in Oncology*, **2021**, 22, 45 | 5.4 | 5 |
| 78 | International Experts Panel Meeting of the Italian Association of Thoracic Oncology on Antiangiogenetic Drugs for Non-Small Cell Lung Cancer: Realities and Hopes. *Journal of Thoracic Oncology*, **2016**, 11, 1153-69 | 8.9 | 5 |
| 77 | Reactivation of hepatitis B virus in cancer patients treated with chemotherapy for solid tumors. Is the prophylaxis really required?. *Digestive and Liver Disease*, **2017**, 49, 197-201 | 3.3 | 4 |
| 76 | A Tribute to John Mendelsohn: A Pioneer in Targeted Cancer Therapy. *Cancer Research*, **2019**, 79, 4315-4323 | 12.1 | 4 |
| 75 | Spectroscopic Characterization and Cytotoxicity Assessment towards Human Colon Cancer Cell Lines of Acylated Cycloartane Glycosides from L. *Molecules*, **2019**, 24, | 4.8 | 4 |
| 74 | Durable Complete Radiological Response to Nivolumab in Two Heavily Pretreated Western Elderly Patients With Metastatic Gastric Cancer: A Case Report. *Frontiers in Oncology*, **2020**, 10, 130 | 5.3 | 4 |

| | | | |
|---|---|---|---|
| 73 | The potential role of bevacizumab in early stages and locally advanced non-small cell lung cancer. *Therapeutic Advances in Medical Oncology*, **2009**, 1, 5-13 | 5.4 | 4 |
| 72 | Immunotherapy for Biliary Tract Cancer in the Era of Precision Medicine: Current Knowledge and Future Perspectives.. *International Journal of Molecular Sciences*, **2022**, 23, | 6.3 | 4 |
| 71 | Health-Related Quality of Life in Oral Cancer Patients: Scoping Review and Critical Appraisal of Investigated Determinants. *Cancers*, **2021**, 13, | 6.6 | 4 |
| 70 | Holistic Approach to Immune Checkpoint Inhibitor-Related Adverse Events.. *Frontiers in Immunology*, **2022**, 13, 804597 | 8.4 | 4 |
| 69 | Nab-paclitaxel plus gemcitabine as first line therapy in metastatic pancreatic cancer patients relapsed after gemcitabine adjuvant treatment. *Medical Oncology*, **2019**, 36, 83 | 3.7 | 3 |
| 68 | Implications of KRAS mutation status for the treatment of metastatic colorectal cancer. *Targeted Oncology*, **2009**, 4, 311-22 | 5 | 3 |
| 67 | Combination of epidermal growth factor receptor inhibitors and antiangiogenic drugs: a model for treatment. *Targeted Oncology*, **2006**, 1, 123-129 | 5 | 3 |
| 66 | Epidermal growth factor receptor inhibitors in non-small-cell lung cancer. *Expert Opinion on Drug Discovery*, **2007**, 2, 335-48 | 6.2 | 3 |
| 65 | Zd1839 (Iressa) Preclinical Studies and Pharmacology. *Tumori*, **2002**, 88, S155-S157 | 1.7 | 3 |
| 64 | Reduction of RI alpha subunit of cAMP-dependent protein kinase expression induces growth inhibition of human mammary epithelial cells transformed by TGF-alpha, c-Ha-ras, and c-erbB-2 genes. *Annals of the New York Academy of Sciences*, **1993**, 698, 102-7 | 6.5 | 3 |
| 63 | Health-related quality of life in the early-access phase IIIb study of trifluridine/tipiracil in pretreated metastatic colorectal cancer (mCRC): Results from PRECONNECT study.. *Journal of Clinical Oncology*, **2019**, 37, 638-638 | 2.2 | 3 |
| 62 | Light Alcohol Drinking and the Risk of Cancer Development: A Controversial Relationship. *Reviews on Recent Clinical Trials*, **2020**, 15, 164-177 | 1.2 | 3 |
| 61 | Baseline IFN- and IL-10 expression in PBMCs could predict response to PD-1 checkpoint inhibitors in advanced melanoma patients. *Scientific Reports*, **2020**, 10, 17626 | 4.9 | 3 |
| 60 | Trifluridine/tipiracil plus bevacizumab for third-line management of metastatic colorectal cancer: SUNLIGHT study design. *Future Oncology*, **2021**, 17, 1977-1985 | 3.6 | 3 |
| 59 | Exploratory findings from a prematurely closed international, multicentre, academic trial: RAVELLO, a phase III study of regorafenib versus placebo as maintenance therapy after first-line treatment in RAS wild-type metastatic colorectal cancer. *ESMO Open*, **2019**, 4, e000519 | 6 | 3 |
| 58 | Alternative macrophage polarisation associated with resistance to anti-PD1 blockade is possibly supported by the splicing of FKBP51 immunophilin in melanoma patients. *British Journal of Cancer*, **2020**, 122, 1782-1790 | 8.7 | 3 |
| 57 | Increased circulating levels of vascular endothelial growth factor C can predict outcome in resectable gastric cancer patients. *Journal of Gastrointestinal Oncology*, **2019**, 10, 314-323 | 2.8 | 2 |
| 56 | Combination of standard chemotherapy and targeted agents. *Journal of Thoracic Oncology*, **2007**, 2, S19-23 | 8.9 | 2 |

| | | | |
|---|---|---|---|
| 55 | Capecitabine plus weekly oxaliplatin in gastrointestinal tumors: a phase I study. *American Journal of Clinical Oncology: Cancer Clinical Trials*, **2006**, 29, 85-9 | 2.7 | 2 |
| 54 | Multi-Omic Approaches in Colorectal Cancer beyond Genomic Data.. *Journal of Personalized Medicine*, **2022**, 12, | 3.6 | 2 |
| 53 | Optimal treatment strategy in KRAS wild type (wt) metastatic colorectal cancer (mCRC): Cetuximab plus FOLFIRI followed by FOLFOX4 with or without cetuximab-The Capri trial from the Gruppo Oncologico Dell□talia Meridionale (GOIM).. *Journal of Clinical Oncology*, **2013**, 31, e14565-e14565 | 2.2 | 2 |
| 52 | Phase III study of regorafenib versus placebo as maintenance therapy in RAS wild type metastatic colorectal cancer (RAVELLO trial).. *Journal of Clinical Oncology*, **2015**, 33, TPS3634-TPS3634 | 2.2 | 2 |
| 51 | Therapeutic dual inhibition of HER2 pathway for metastatic colorectal cancer (mCRC): The HERACLES trial.. *Journal of Clinical Oncology*, **2015**, 33, 565-565 | 2.2 | 2 |
| 50 | A phase III, double-blind, randomized study of pamiparib versus placebo as maintenance therapy in patients with inoperable, locally advanced, or metastatic gastric cancer (GC) that responded to platinum-based first-line chemotherapy.. *Journal of Clinical Oncology*, **2019**, 37, TPS173-TPS173 | 2.2 | 2 |
| 49 | Skin Toxicity as Predictor of Survival in Refractory Patients with Wild-Type Metastatic Colorectal Cancer Treated with Cetuximab and Avelumab (CAVE) as Rechallenge Strategy. *Cancers*, **2021**, 13, | 6.6 | 2 |
| 48 | Dual inhibition of TGF□and AXL as a novel therapy for human colorectal adenocarcinoma with mesenchymal phenotype. *Medical Oncology*, **2021**, 38, 24 | 3.7 | 2 |
| 47 | Novel Cancer Models for Optimizing Anti-EGFR Therapies. *Clinical Cancer Research*, **2018**, 24, 727-729 | 12.9 | 2 |
| 46 | Translational Insights and New Therapeutic Perspectives in Head and Neck Tumors. *Biomedicines*, **2021**, 9, | 4.8 | 2 |
| 45 | Retrospective Study of Regorafenib Versus TAS-102 Efficacy and Safety in Chemorefractory Metastatic Colorectal Cancer (mCRC) Patients: A Multi-institution Real Life Clinical Data. *Clinical Colorectal Cancer*, **2021**, 20, 227-235 | 3.8 | 2 |
| 44 | Immunotherapy for head and neck cancer: present and future.. *Critical Reviews in Oncology/Hematology*, **2022**, 103679 | 7 | 2 |
| 43 | Genetic Landscape of Primary Versus Metastatic Colorectal Cancer: to What Extent Are They Concordant?. *Current Colorectal Cancer Reports*, **2015**, 11, 217-224 | 1 | 1 |
| 42 | Asymptomatic azygos vein overflow in a young patient with primary mediastinal seminoma. *Thoracic Cancer*, **2019**, 10, 2308-2311 | 3.2 | 1 |
| 41 | Treatment decision-making for advanced non-small cell lung cancer and differences among European countries: 1st AIOT-ETOP meeting. *Lung Cancer*, **2011**, 74, 544-8 | 5.9 | 1 |
| 40 | Re: Biomarkers predicting clinical outcome of epidermal growth factor receptor-targeted therapy in metastatic colorectal cancer. *Journal of the National Cancer Institute*, **2010**, 102, 573; author reply 573-5 | 9.7 | 1 |
| 39 | Phase III study of regorafenib versus placebo as maintenance therapy in RAS wild type metastatic colorectal cancer (RAVELLO trial).. *Journal of Clinical Oncology*, **2015**, 33, TPS789-TPS789 | 2.2 | 1 |
| 38 | Mixed Neuroendocrine Non-Neuroendocrine Neoplasms of the Gastrointestinal Tract: A Case Series.. *Healthcare (Switzerland)*, **2022**, 10, | 3.4 | 1 |

| | | | |
|---|---|---|---|
| 37 | Reply to S. Debska-Szmich et al. *Journal of Clinical Oncology*, **2015**, 33, 3518 | 2.2 | 0 |
| 36 | Treatment of Cutaneous Melanoma Harboring SMO p.Gln216Arg Mutation with Imiquimod: An Old Drug with New Results. *Journal of Personalized Medicine*, **2021**, 11, | 3.6 | 0 |
| 35 | PARALLEL 303: Phase 2 randomized study of pamiparib vs placebo as maintenance therapy in patients (pts) with inoperable locally advanced or metastatic gastric cancer that responded to platinum-based first-line (1L) chemotherapy.. *Journal of Clinical Oncology*, **2021**, 39, 3109-3109 | 2.2 | 0 |
| 34 | Chemotherapy-induced neutropenia and treatment efficacy in advanced non-small-cell lung cancer: a pooled analysis of 6 randomized trials. *BMC Cancer*, **2021**, 21, 549 | 4.8 | 0 |
| 33 | Anti-tumor activity of cetuximab plus avelumab in non-small cell lung cancer patients involves innate immunity activation: findings from the CAVE-Lung trial.. *Journal of Experimental and Clinical Cancer Research*, **2022**, 41, 109 | 12.8 | 0 |
| 32 | Prognostic Relevance of Progesterone Receptor Levels in Early Luminal-Like HER2 Negative Breast Cancer Subtypes: A Retrospective Analysis.. *Frontiers in Oncology*, **2022**, 12, 813462 | 5.3 | 0 |
| 31 | Immunotherapy in advanced anal cancer: Is the beginning of a new era?. *Cancer Treatment Reviews*, **2022**, 105, 102373 | 14.4 | 0 |
| 30 | The Cancer Moonshot from a European perspective. *Lancet Oncology, The*, **2017**, 18, e626 | 21.7 | |
| 29 | Optimization of the Development of Old and New EGFR and MAP Kinase Inhibitors for Colorectal Cancer. *Current Colorectal Cancer Reports*, **2014**, 10, 279-287 | 1 | |
| 28 | Predictive biomarkers to anti-EGF receptor inhibitors in the treatment of metastatic colorectal cancer. *Colorectal Cancer*, **2014**, 3, 299-308 | 0.8 | |
| 27 | Delivery optimization of erlotinib according to toxicity: may clinical practice go beyond research?. *Lung Cancer*, **2013**, 80, 352-3 | 5.9 | |
| 26 | Management of EGFR-mutant non-small-cell lung cancer patients after first-line reversible EGF receptor-tyrosine kinase inhibitors. *Lung Cancer Management*, **2014**, 3, 77-84 | 2.6 | |
| 25 | Reply to V. Lorusso et al. *Journal of Clinical Oncology*, **2013**, 31, 289-9 | 2.2 | |
| 24 | Reply to M.J. Rother. *Journal of Clinical Oncology*, **2011**, 29, 4207-4208 | 2.2 | |
| 23 | Is there a role for maintenance therapy in advanced non-small-cell lung cancer?. *Clinical Practice (London, England)*, **2012**, 9, 77-86 | 3 | |
| 22 | Clinico-Pathologic and Biologic Predictors of EGFR Inhibitors Activity and Efficacy in Lung and in Colorectal Cancer. *Current Signal Transduction Therapy*, **2008**, 3, 234-243 | 0.8 | |
| 21 | Effect of cetuximab in recurrent and refractory squamous cell carcinoma of the head and neck (SCCHN): a case report. *Targeted Oncology*, **2007**, 2, 253-257 | 5 | |
| 20 | Vandetanib, A Dual Inhibitor of VEGFR and EGFR Tyrosine Kinase Activity. *Current Cancer Therapy Reviews*, **2007**, 3, 236-241 | 0.4 | |

| | | |
|---|---|---|
| 19 | Cetuximab, A Chimeric Anti-Epidermal Growth Factor Receptor Monoclonal Antibody, in Colorectal Cancer Treatment. *Current Cancer Therapy Reviews*, **2007**, 3, 242-248 | 0.4 |
| 18 | Combination of Anti-EGFR Drugs and Other Molecular Targeted Agents as Anti-Cancer Strategy. *Current Cancer Therapy Reviews*, **2007**, 3, 117-126 | 0.4 |
| 17 | Mechanisms of Intrinsic and Acquired Resistance to EGFR Inhibitors. *Current Cancer Therapy Reviews*, **2007**, 3, 276-283 | 0.4 |
| 16 | Small Molecule Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitors in Non Small Cell Lung Cancer Treatment. *Current Cancer Therapy Reviews*, **2007**, 3, 226-235 | 0.4 |
| 15 | Editorial [ The Role of Epidermal Growth Factor Receptor (EGFR) Targeting Drugs in the Treatment of Cancer Guest Editor: Fortunato Ciardiello ]. *Current Cancer Therapy Reviews*, **2007**, 3, 223-225 | 0.4 |
| 14 | The Epidermal Growth Factor Receptor Pathway as a Selective Molecular-Targeted Treatment in Human Breast Cancer **2006**, 177-191 | |
| 13 | Cripto **2003**, 330-334 | |
| 12 | Increased circulating levels of VEGF-C to predict outcome in resectable gastric cancer patients.. *Journal of Clinical Oncology*, **2014**, 32, 4080-4080 | 2.2 |
| 11 | Combination nab-paclitaxel (Nab-P) plus gemcitabine (G) as first-line treatment in advanced pancreatic cancer (APC): Our experience.. *Journal of Clinical Oncology*, **2014**, 32, e15257-e15257 | 2.2 |
| 10 | Safety and tolerability of regorafenib (REG) in Italian patients: Subgroup analysis of the phase III CORRECT study in metastatic colorectal cancer (mCRC).. *Journal of Clinical Oncology*, **2014**, 32, e14613-e14613 | 2.2 |
| 9 | Correlation of 12-weeks decrease of CA19.9 with overall response rate (ORR) and progression-free survival (PFS) in advanced pancreatic cancer (APC) patients (pts) treated with first-line nab-paclitaxel (Nab-P) and gemcitabine (G).. *Journal of Clinical Oncology*, **2014**, 32, e15256-e15256 | 2.2 |
| 8 | Regional variation in physicians awareness, understanding, and use of personalized medicine in the treatment of cancer and perception of patient (pt) education.. *Journal of Clinical Oncology*, **2015**, 33, 574-574 | 2.2 |
| 7 | The pretreatment neutrophil-lymphocyte ratio (NLR) as a predictor of outcome in a cohort of metastatic pancreatic cancer patients treated with nab-paclitaxel and gemcitabine.. *Journal of Clinical Oncology*, **2015**, 33, e15224-e15224 | 2.2 |
| 6 | Trastuzumab Resistance in Breast Cancer **2011**, 51-60 | |
| 5 | Clinical results with EGFR inhibitors in colorectal cancer **2012**, 44-59 | |
| 4 | Small bowel metastasis from pancreatic cancer in a long-term survival patient with synchronous advanced malignant pleural mesothelioma: A case report and literature review. *Oncology Letters*, **2016**, 12, 4505-4509 | 2.6 |
| 3 | Educational needs in gastrointestinal cancer: a consensus position paper from the ESMO Gastrointestinal Cancer Faculty. *ESMO Open*, **2019**, 4, e000533 | 6 |
| 2 | How to incorporate a chemo-free interval into the management of metastatic colorectal cancer. *Clinical Advances in Hematology and Oncology*, **2020**, 18 Suppl 16, 1-24 | 0.6 |

| | | |
|---|---|---|
| 1 | Why chemo-free treatment intervals can improve care of patients with metastatic colorectal cancer. *Clinical Advances in Hematology and Oncology*, **2020**, 18 Suppl 16, 3-5 | 0.6 |